Recently Featured

CHMP Recommends Six New Medicines for Approval at June 2026 Meeting

July 12, 2026
At its June 2026 meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended six new medicines for approval, marking a significant step forward in therapeutic options for various conditions. Among the notable recommendations are Aujemflu, an influenza vaccine developed by Seqirus Netherlands, and Hopledo, a treatment for Parkinson’s disease from Zambon S.p.A. Additionally,…

Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy

July 12, 2026
Absci has secured $100 million in financing to advance its candidate ABS-201, targeting endometriosis and pattern hair loss. This funding comes on the heels of promising Phase I data, which suggests the potential efficacy of ABS-201 in addressing these significant health concerns. The investment reflects growing confidence in Absci’s innovative approach to drug development, particularly…

New ACIP Charter Broadens Criteria for Members, Calls for Review of Alternatives to Vaccines

July 12, 2026
A new charter for the Advisory Committee on Immunization Practices (ACIP), which advises the Centers for Disease Control and Prevention (CDC) on vaccine use, significantly alters the committee’s focus. The revised charter shifts away from a primary emphasis on recommending new vaccines, instead placing a greater responsibility on the committee to evaluate alternatives for disease…

Ionis Grants Recordati Rights to Zilganersen for Alexander Disease

July 12, 2026
Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialize zilganersen for the treatment of Alexander disease (AxD) in countries outside the United States. This strategic partnership marks a significant step in the advancement of therapies for rare neurological conditions, particularly as AxD currently lacks approved treatment options. The collaboration not only underscores Ionis’s…

Ongoing Cases